Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zarate

Showing results (151-160 of 707) with videos related to

Pageof 71
Sort By:
Physiological Reports|September 7, 2016
Ketamine modulates fetal hemodynamic and endocrine responses to umbilical cord occlusionMiguel A Zarate, Eileen I Chang, Andrew Antolic, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 13, 2013
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Mark J Niciu, Ioline D Henter, Gerard Sanacora, et al.
Focus (American Psychiatric Publishing)|December 21, 2020
Prognosis and Improved Outcomes in Major Depression: A ReviewChristoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1977
Suppressor cell activation by anti-thy 1.2 in NZB/WF1 miceL W Klassen, A Zarate, M C Gelfand, et al.
Frontiers in Psychiatry|February 12, 2021
New Methods for Assessing Rapid Changes in Suicide RiskElizabeth D Ballard, Jessica R Gilbert, Christina Wusinich, et al.
Nature Reviews. Drug Discovery|April 22, 2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersGerard Sanacora, Carlos A Zarate, John H Krystal, et al.
Translational Psychiatry|April 5, 2019
Prognosis and improved outcomes in major depression: a reviewChristoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
Psychopharmacology|April 23, 2022
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptorsHildegard A Wulf, Caroline A Browne, Carlos A Zarate, et al.
The Primary Care Companion for CNS Disorders|October 16, 2014
Pharmacologic treatment of dimensional anxious depression: a reviewDawn F Ionescu, Mark J Niciu, Erica M Richards, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|December 23, 2020
Introduction to the special issue on Clinical Genetics in Latin AmericaCarlos E Prada, Denise Cavalcanti, Ida Vanessa Doederlein Schwartz, et al.
Pageof 71

Showing results (151-160 of 707) with videos related to

Sort By:
Pageof 71
Physiological Reports|September 7, 2016
Ketamine modulates fetal hemodynamic and endocrine responses to umbilical cord occlusionMiguel A Zarate, Eileen I Chang, Andrew Antolic, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 13, 2013
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Mark J Niciu, Ioline D Henter, Gerard Sanacora, et al.
Focus (American Psychiatric Publishing)|December 21, 2020
Prognosis and Improved Outcomes in Major Depression: A ReviewChristoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1977
Suppressor cell activation by anti-thy 1.2 in NZB/WF1 miceL W Klassen, A Zarate, M C Gelfand, et al.
Frontiers in Psychiatry|February 12, 2021
New Methods for Assessing Rapid Changes in Suicide RiskElizabeth D Ballard, Jessica R Gilbert, Christina Wusinich, et al.
Nature Reviews. Drug Discovery|April 22, 2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersGerard Sanacora, Carlos A Zarate, John H Krystal, et al.
Translational Psychiatry|April 5, 2019
Prognosis and improved outcomes in major depression: a reviewChristoph Kraus, Bashkim Kadriu, Rupert Lanzenberger, et al.
Psychopharmacology|April 23, 2022
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptorsHildegard A Wulf, Caroline A Browne, Carlos A Zarate, et al.
The Primary Care Companion for CNS Disorders|October 16, 2014
Pharmacologic treatment of dimensional anxious depression: a reviewDawn F Ionescu, Mark J Niciu, Erica M Richards, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|December 23, 2020
Introduction to the special issue on Clinical Genetics in Latin AmericaCarlos E Prada, Denise Cavalcanti, Ida Vanessa Doederlein Schwartz, et al.
Pageof 71